Anti-Human C5 (Ravulizumab) (C3290-5mg)

Complement component 5 (C5) is a crucial protein in the complement system, part of the body’s immune response. It is synthesized in the liver. It circulates in the blood as an inactive precursor. When triggered, C5 splits into C5a and C5b. C5a acts as an inflammation promoter and attracts immune cells to the sites of infection. C5b kickstarts the creation of a membrane attack complex (MAC), which creates pores in the membranes of pathogens, leading to their destruction. Irregularities in C5 activation are linked to illnesses such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS)1,2. ALXN-1210, also known as ravulizumab, is a human monoclonal antibody. This antibody specifically targets and inhibits C5, preventing its cleavage into C5a and C5b, thus blocking (MAC) formation. Ravulizumab serves as a lasting inhibitor of C5 designed for effect with less frequent dosing compared to its precursor eculizumab. Clinical studies have shown that ravulizumab effectively treats conditions like PNH and aHUS offering patients convenience and quality of life due, to its dosing intervals3-5.